Tue, Oct 21, 2014, 5:58 AM EDT - U.S. Markets open in 3 hrs 32 mins


% | $
Quotes you view appear here for quick access.

Osiris Therapeutics, Inc. Message Board

vincenzo01 9 posts  |  Last Activity: Oct 13, 2014 9:13 AM Member since: Apr 3, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • This is an approximation based on memory, but last quarter, ending about 30 June, OSIR earnings came in at a $66,000 loss due to a substantial decline in the value of its Mesoblast stock holding. I think it was a roughly $2.5 million decline in the value of MSB.AX. Since then, MSB.AX has actually closed the most recent quarter a little higher. Based on eye-balling its chart on Yahoo, the MSB value on 30 June was about $4.20 and on 30 Sept it was higher than that. So OSIR earnings for the most recent qtr should a bit higher based on the increase of th evalue of the MSB shares OSIR holds.

  • Reply to

    Investment Account

    by ozark580 Sep 2, 2014 8:52 PM
    vincenzo01 vincenzo01 Sep 3, 2014 8:19 AM Flag

    Footnote: My recollection is that for the last quarter, Osiris reported a loss of about $2.5 million on the decline in the value of the Mesoblast stock.it has owned since the sale of Prochymal. That paper loss changed the last quarter's bottom line from being a strong gain to being a tiny loss of $66,000. I hope our Treasurer Phil J can do some creative accounting for the current quarter so our bottom line is not sky high profit. Perhaps that's a fine problem to have.

  • Reply to

    It's Time to Change the Name

    by tensgut Aug 20, 2014 8:59 AM
    vincenzo01 vincenzo01 Aug 20, 2014 10:04 AM Flag

    Osiris Regenerative Biotechnology, Inc

  • Today Zacks announcement compounded its fuzzy logic by repeating that the consensus earnings for the 2nd qtr for OSIR was for .30/share. As Ozark noted earlier, that projection by one so-called analyst, seemed rooted in a strategy geared to assist shorts and having no connection with reality. Not even shorts have any faith in that failed strategy., as perhaps implied in today's buy side volume.

  • Reply to

    What's with the volume?

    by minnesotafarmcountry Aug 11, 2014 9:32 AM
    vincenzo01 vincenzo01 Aug 11, 2014 1:18 PM Flag

    All this unusual buying volume could very well be smart shorts closing out their positions. The gigantic increase of revenue in the 2nd qtr and clear prospects for continued growth for Q3 and Q4, it seems highly likely that the OSIR pps has reached a tipping point and it is no longer has favorable odds for continued shorting. GLTA

  • vincenzo01 vincenzo01 Aug 7, 2014 8:30 AM Flag

    Additional info from the EDGAR filing:

    “It is very encouraging that the quarter-over-quarter revenue growth of 32% was largely driven by our new wound care sales team,” said Lode Debrabandere, Ph.D., President and Chief Executive Officer of Osiris. “Revenue growth and bottom line improvement were impressive while we continue to invest and differentiate our products scientifically, clinically and through regulatory strategies.”

    Second Quarter Financial Results

    Product revenues during the second quarter of 2014 were $13.3 million, compared to $5.3 million during the second quarter of 2013, an increase of 151%. Gross margin during the second quarter was 78% compared to 72% during the second quarter of 2013. Gross profit was $10.4 million during the second quarter of 2014 and $3.8 million during the same period of 2013. The net loss from overall continuing operations was $1.4 million in the second quarter of 2014 after recognizing the net $1.3 million non-cash loss in market value of stock received from the Mesoblast transaction and income taxes of $130,000. As of June 30, 2014, Osiris had $80.9 million of cash, investments and trade receivables.

    Research and development expenses for the second quarter of 2014 were $1.1 million, an increase from the $0.7 million incurred in the first quarter of this year. As a result of our increased commercial activity, our selling, general and administrative expenses were $9.3 million for the second quarter of 2014, compared to $4.2 million for the same period of the prior year.

  • Osiris Therapeutics Announces Second Quarter 2014 Financial Results: Revenue Up 32% Over Previous Quarter

    COLUMBIA, Md. — August 7, 2014 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets announced today its financial results for the second quarter of 2014.

    Highlights and Recent Developments

    · Increased product revenue for the quarter to $13.3 million - a 151% increase over Q2 2013 and a 32% increase over previous quarter.

    · Held gross margin steady at 78% — gross profit increased 172% over Q2 2013 and 32% over previous quarter.

    · Completed the quarter with a loss from continuing operations (excl. non-cash items) of $66,000.

    · Obtained Medicare coverage in 10 states, representing 27% of Medicare-insured lives.

    · Published manuscript in the International Wound Journal from Osiris’ multi-center (n=20), randomized, controlled clinical trial, Protocol 302, which demonstrated overwhelming efficacy of Grafix® compared to control in the closure of diabetic foot ulcers over 12 weeks (62% vs. 21.3%, p=0.0001, n=97).

    · Agreed on path forward with FDA to complete a Biologics License Application for Grafix in order to obtain additional claims and indications.

    · Added several new sizes to the Grafix product line, giving health care providers the ability to optimally match Grafix to the wound size, reduce overall treatment costs and eliminate concerns regarding product waste. Grafix is well-positioned to remain a cost effective option within the Centers for Medicare & Medicaid Services bundled payment system.

    “It is very encouraging that the quarter-over-quarter revenue growth of 32% was largely driven by our new wound care sales team,” said Lode Debrabandere, Ph.D., President and Chief Exec

  • Tonight, MSB announced it is conducting a study using mesenchymal cells. Are they using OSIR's research?

    National Institutes of Health and Mesoblast Enter Into Agreement for 120-Patient Trial In End-Stage Heart Failure

    NEW YORK and MELBOURNE, Australia, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the signing of an agreement with the United States National Institutes of Health's (NIH) National Heart, Lung and Blood Institute to collaborate on a trial using Mesoblast's proprietary adult stem cell therapy to treat patients with advanced heart failure requiring an implantable left ventricular assist device (LVAD) to maintain circulatory support. The National Institute of Neurological Disorders and Stroke, part of the NIH, and the Canadian Institutes for Health Research are also supporting this trial.

    The key objectives of using Mesoblast's Mesenchymal Precursor Cells (MPCs) in end-stage heart failure patients are to improve heart muscle function sufficiently to reduce the need for LVAD support, and to reduce the long-term complications of LVAD implantation which result in recurrent hospitalizations.

    Sentiment: Buy

  • Relatively strong buying began about 9:40 a.m. starting with trades in the 4k to 5k shares range, then with a couple of buy-side trades in the 10k to 19k range by 10:46 a.m., followed by consistent smaller buys in the 1k volume range up to about 10:25 a.m, by which time the share price was at $15.20 (+.70) . By that time 60k shares had traded. A bit of profit taking seemed to come in after 10:40 a.m. with smaller blocks less than 1k shares.adding a little pressure to the downside. Given the diversity of sizes of buying blocks, I wonder if it could have been due to some published positive recommendation, although I've seen no such publicity. My apology for the detailed and ephemeral nature of this post which adds little to our conversation. But it's info as we look toward 7August's earnings announcement.

12.92+0.22(+1.73%)Oct 20 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
NCR Corp.
NYSEMon, Oct 20, 2014 4:02 PM EDT